From advances in diabetes research to record approval of drugs to treat rare diseases, taxpayer funded research and the effective employment of regulatory tools played a significant role in improving the health and wellbeing of Americans in 2014. Below is a year-end roundup of research highlights and scientific achievements from the National Institutes of Health, Centers for Disease Control and Prevention, National Science Foundation, Food and Drug Administration and Agency for Healthcare Research and Quality.
- NIH 2014 Research Highlights
- CDC Year in Review: “Mission Critical”
- NSF Discoveries
- FDA’s 2014 Drug Approvals: Speeding Novel Drugs to Patients Who Need Them
- AHRQ 2014 Impact Case studies
To fuel this momentum in scientific discovery and development, policymakers must commit to robust funding for the federal health agencies and policies that support private sector innovation. Take action today and tell your elected officials to make research for health a higher national priority in the 114th Congress.
Coulter. Medical diagnostics.
See a link?
Coulter is one-half of Beckman Coulter, a Research!America member and a company that boasts nearly $6 billion in market capitalization. And that half of a multi-billion-dollar, multinational company began with research on paint for the U.S. Navy.
Such unlikely beginnings are the reason that Wallace Coulter has been named the first recipient of the Golden Goose Award for 2013. More winners will be named during the coming months.
The press release announcing the award explains Coulter’s research: In his time away from working for various electronics companies in the 1940s, Coulter built a lab in his garage and earned a grant from the Office of Naval Research. His task was to standardize the solid particles in the paint the Navy was using on its warships; but to do that, he first had to identify the reasons for inconsistencies among the paints.
He developed a device that would help him count the number of particles in a given volume of paint. Comparing different colors and batches would help him understand how to standardize. Continue reading →
On December 3, Policy Cures released its fifth annual G-FINDER report, a comprehensive survey of funding for research and development for neglected diseases. The report tracks global public, private and philanthropic investments into R&D for 31 diseases, including HIV/AIDS, tuberculosis, malaria and NTDs. In positive news, this year’s report shows that total funding has actually increased by $443 million since 2007.
The report demonstrates that government funding, which accounts for over two-thirds of all investment, is increasingly going toward basic academic research, rather than product development. Research!America believes it is vital that the entire research pipeline be fully funded. Basic research will help us understand the best ways to tackle these neglected diseases and give us a better understanding of disease and the human body. However, we also need robust funding for the development of urgently needed tools like drugs, vaccines and diagnostics. This urgency is worsened by the fact that private and philanthropic investments in product development for NTDs have also decreased.
Because NTDs disproportionately affect the “bottom billion” or individuals earning less than $1.25 per day, there is essentially no market demand for new NTD tools, so the private sector is unlikely to fund these projects. Dr. Moran, director of Policy Cures, believes that governments must step up to the plate, saying that “if [governments] want products for neglected diseases, they must fund product development as well as basic research.”
-Morgan McCloskey, global health intern